All NICE articles
-
Industry newsNICE increases access to SGLT-2 inhibitors medicines to help treat type 2 diabetes
This industry news update is on SGLT-2 inhibitors that NICE are expanding access for as an alternative treatment for type 2 diabetes.
-
Industry newsNICE rejects funding for Lecanemab as treatment benefits ‘remain too small’
The National Institute for Health and Care Excellence (NICE) has recently announced that it will not back funding for the Lecanemab due to concerns about its effectiveness.
-
JournalThe health economics profile of new pharmaceuticals
The current article discusses elements of the health economics profile of new pharmaceuticals, specifically looking at the challenges of providing a healthcare system, the concepts around the provision of value-based healthcare systems and calculating the cost-effectiveness of new medicines. A quality-adjusted life year (QALY) is a concept used in health ...